City of Hope Chicago
Zion, Illinois 60099
9 studies enrolling now · 10 studies all time
What they study most
Advanced Renal Cell Carcinoma, Advanced or Metastatic Renal Cell Carcinoma, Breast Cancer, Metastatic, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Renal Cell Metastasis, Carcinoma, Renal Cell, Advanced, Clear Cell Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Hematologic Malignancies, Hodgkin Lymphoma, Lymphoma
Studies at this site
- Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) — Recruiting now
- A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) — Recruiting now
- A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma — Recruiting now
- Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML — Recruiting now
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer — Recruiting now
- ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer — Recruiting now
- A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma — Recruiting now
- Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
- Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer — Running, not enrolling
- Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Participants With Multiple Myeloma — Available (expanded access)